What Grade 4 cartilage loss means in practice

Being told you have Grade 4 cartilage damage — or that your knee is 'bone on bone' — is a significant moment, but the phrase covers a wider range of clinical situations than most patients realise. Understanding exactly what it means is the starting point for any honest conversation about treatment.

Under the ICRS (International Cartilage Repair Society) classification, Grade 4 is the most severe tier of focal chondral damage: the cartilage has eroded entirely through its full thickness, through the calcified layer beneath, to leave subchondral bone directly exposed. Nothing remains of the original articular surface at that site. Unlike skin or bone, articular cartilage has no blood supply — it relies entirely on synovial fluid diffusion for nutrition — and no nerve supply. This matters clinically because the inflammatory cascade that normally triggers tissue repair never reaches a chondral defect. A Grade 4 lesion cannot self-repair. Left unaddressed, exposed bone grinds against opposing surfaces, accelerating joint damage and sustaining a degenerative pain cycle.

The question that shapes every subsequent treatment decision is not simply whether cartilage has gone, but where and how much. A contained focal defect — a discrete crater, typically at a single site such as the medial femoral condyle, surrounded by structurally intact cartilage — is an entirely different clinical problem from diffuse, multi-compartmental loss affecting two or three knee compartments simultaneously. Both may produce 'bone-on-bone' appearances on imaging; both may produce similar pain; but they call for different interventions, and conflating them leads to treatment mismatches.

Precise characterisation of the defect — its size in cm², depth, location, and the condition of the surrounding cartilage and subchondral bone — is what distinguishes the two scenarios. Modern MRI assessment, including cartilage-specific techniques such as T2 mapping and cartilage segmentation (available at Lincolnshire Knee via onMRI™ AI-assisted analysis), can map a lesion far more accurately than a plain X-ray or symptom history alone. That mapping is what the rest of the suitability question turns on.

How ChondroFiller works as an injectable collagen scaffold

ChondroFiller™ is a CE-marked Class III acellular Type I collagen hydrogel — a scaffold material, not a cell therapy. No donor cells are injected; the product's role is to provide a temporary three-dimensional matrix that the body can colonise using its own resources.

The mechanism is called acellular matrix-induced chondrogenesis. Once placed into the defect, the collagen gel sets in situ and creates a structured environment that draws mesenchymal and chondrocyte-lineage progenitor cells from the surrounding synovium and subchondral bone into the lesion. A 2025 ex vivo study using femoral condyle specimens from knee patients demonstrated a 2.4-fold increase in DNA content within ChondroFiller-treated defects by day 14, compared with untreated controls — direct laboratory evidence of this cell-recruitment process occurring at the cartilage surface. The appropriate way to describe what follows is that the scaffold supports the body's own repair processes; it does not regrow cartilage in the way a graft restores tissue volume.

In clinical practice, the treatment is delivered as an ultrasound-guided outpatient injection. There is no general anaesthetic, no arthroscopic approach, and no surgical incision. Image guidance allows precise placement of the collagen material into the target defect site during a clinic appointment.

One practical point to discuss during assessment concerns post-injection loading. A 2024 biomechanical study confirmed that freshly placed ChondroFiller has limited mechanical stability under cyclic load, meaning full weight-bearing is protected until stable defect filling is established on follow-up imaging. This is a standard part of the post-injection protocol, not an exceptional restriction.

When Grade 4 loss fits the ChondroFiller indication

Grade 4 knee cartilage loss sits squarely within ChondroFiller's approved indication window — ICRS Grade III through Grade IV — which means bone-on-bone confirmation on MRI is a positive clinical finding for scaffold candidacy, not a reason to rule it out.

The evidence for suitable patients is consistent across the published series. In a 2016 multicentre randomised controlled trial (n=23) comparing ChondroFiller liquid with microfracture in focal knee defects, the ChondroFiller group showed statistically significant improvements in IKDC scores at 3, 6, and 12 months, with good immediate defect filling confirmed on MOCART MRI and progressive cartilage maturation across the follow-up period. No adverse events were recorded. A 2024 prospective knee cohort from Bulgaria (n=17, mean age 31) replicated these functional gains: both Lysholm and IKDC scores improved significantly, reaching a plateau between 6 and 12 months — consistent with the scaffold maturation timeline visible on imaging. Across more than 19,000 cases performed internationally, the headline benchmarks are approximately +30 IKDC points in knee patients and MOCART cartilage regeneration scores of 70 to 87.

The patient profile that best matches this evidence is a focal, contained single-site defect with no significant background osteoarthritis in the wider joint, and sufficient motivation for a structured post-injection rehabilitation period. Age is not a limiting factor for the injection pathway. These are focal-disease results and should not be extrapolated to diffuse multi-compartmental involvement — a distinction the next section addresses directly.

When Grade 4 loss rules ChondroFiller out

Not every knee with Grade 4 cartilage loss is a ChondroFiller candidate. The most clinically important distinction is between a focal, contained Grade 4 crater — a discrete lesion in an otherwise functional joint — and diffuse multi-compartmental Grade 4 destruction, where loss is widespread across two or more joint surfaces. The scaffold pathway addresses the former; it cannot compensate for the latter.

The clearest evidence for this comes from a ChondroFiller hip arthroscopy cohort (n=26, 12–60 months follow-up), in which 17 of 21 patients achieved good or excellent results — but every patient with pre-existing Tönnis Grade 2–3 osteoarthritis recorded a poor outcome. The mechanism is directly transferable to the knee: a collagen scaffold placed into a joint already compromised by diffuse degeneration does not have stable, load-bearing surrounding cartilage to integrate with. Kellgren-Lawrence Grade III–IV osteoarthritis on knee imaging places a patient in this category and moves the clinical conversation towards arthroplasty — a well-established, appropriate endpoint for end-stage disease, not a fallback.

Three absolute contraindications apply regardless of defect pattern: an active inflammatory arthritis flare (such as rheumatoid arthritis), active malignancy, and known hypersensitivity to collagen or rat-derived proteins.

Defect size adds a further practical limit. Focal lesions measuring 3 cm² or greater typically require MACI or an osteochondral grafting approach rather than an injectable collagen scaffold alone — a threshold the treating clinician will assess using pre-procedure MRI.

What the evidence shows — and where it is still limited

Two gaps in the evidence base are worth naming plainly before any candidacy decision.

First, no adequately powered randomised controlled trial has yet compared ChondroFiller — delivered by either injection or keyhole surgery — directly with MACI or osteochondral autograft in Grade IV knee defects. The positive functional signals described in earlier sections come from a small RCT and a single-centre cohort totalling fewer than 40 knee patients between them; the 19,000-plus global cases provide meaningful real-world breadth, but case volume is not a substitute for controlled comparative data. Second, published knee-specific outcome data extend only to 12 months in the peer-reviewed literature; five-year comparative figures against microfracture do not yet exist, and sub-site granularity — whether outcomes differ between medial femoral condyle, trochlear, and patellar defects — has not been established in the literature.

None of this undermines the safety profile, which across published series has been consistently favourable with no serious adverse events reported. It does mean that individual assessment carries genuine weight: the decision to use a collagen scaffold for a Grade IV defect cannot yet be guided by large-scale, long-term comparative trial data, and must rely on defect morphology, patient factors, and clinical judgement informed by the best available evidence.

Getting the right assessment for Grade 4 knee damage

Three questions drive any Grade 4 knee assessment: is the defect focal and contained, what is the mechanical load on the affected site, and does the surrounding cartilage provide viable scaffold margins? Imaging establishes the structural picture; biomechanical evaluation of gait and joint-load distribution — available at Lincolnshire Knee via MAI Motion® — adds the functional context that shapes how any treatment will perform once the patient returns to normal activity.

For patients whose Grade 4 pattern falls outside the injectable scaffold window, established pathways exist at each level of severity. Smaller contained defects under approximately 3 cm² may suit microfracture or mosaicplasty. Defects at or above that threshold carry stronger evidence for MACI, which the SUMMIT trial showed produced meaningful KOOS pain and function gains over microfracture at both two and five years. Complex multi-surface lesions point toward osteochondral allografting; diffuse multi-compartmental disease is the clinical territory of arthroplasty — a well-evidenced endpoint in its own right, not a fallback.

The most useful question any Grade 4 patient can bring to a first appointment is not 'am I too far gone?' but 'is my damage focal or diffuse?' — because that single distinction determines which pathway applies.

Lincolnshire Knee is part of the MSK Doctors group and accepts patients without a GP referral. Book an assessment directly at lincolnshireknee.co.uk.

1. [1] Controlled, randomized multicenter study to compare compatibility and safety of ChondroFiller liquid with microfracturing of patients with focal cartilage defects of the knee joint. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
2. [2] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z
3. [3] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
4. [4] Arthroscopic utilization of ChondroFiller gel for treatment of hip articular cartilage defects: cohort 12–60 month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002